xRead Articles - October 2022
355
David E. Rosow, et al
Stability of BTX Dose in SD Patients
CONCLUSION This study has shown that ADSD patients undergoing BTX treatment are likely to experience long-term dose stability, as the odds of dosage change decrease with each subsequent suc cessful injection. Factors such as age, gender, and smoking sta tus were not found to have any effect on dose stability, and patients can be counseled accordingly. Although the overall field of research in this area is somewhat conflicted, this is the largest series of patients studied to date and the only one to make use of logistic regression analysis to determine the rela tionship of demographic variables to dosage stability; further large-scale studies may help clarify the picture. REFERENCES 1. Ludlow CL. Spasmodic dysphonia: a laryngeal control disorder specific to speech. J Neurosci . 2011;31:793–797. 2. Novakovic D, Waters HH, D’Elia JB, Blitzer A. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes. Laryngoscope . 2011;121:606–612. 3. Holden PK, Vokes DE, Taylor MB, Till JA, Crumley RL. Long-term botu linum toxin dose consistency for treatment of adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol . 2007;116:891–896. 4. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spas modic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope . 1998;108:1435–1441.
5. Rosow DE, Parikh P, Vivero RJ, Casiano RR, Lundy DS. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia. Otolaryngol Head Neck Surg . 2013;148:1003–1006. 6. Lundy DS, Lu FL, Casiano RR, Xue JW. The effect of patient factors on response outcomes to Botox treatment of spasmodic dysphonia. J Voice . 1998;12:460–466. 7. Cannito MP, Kahane JC, Chorna L. Vocal aging and adductor spasmodic dysphonia: response to botulinum toxin injection. Clin Interv Aging . 2008;3:131–151. 8. Tanner K, Roy N, Merrill RM, Sauder C, Houtz DR, Smith ME. Case-con trol study of risk factors for spasmodic dysphonia: a comparison with other voice disorders. Laryngoscope . 2012;122:1082–1092. 9. Awan SN. The effect of smoking on the dysphonia severity index in fe males. Folia Phoniatr Logop . 2011;63:65–71. 10. Park KH, Cho SH, Song CE, Kim DH, Kim HT. Neuroimmunological acti vation of the afferent laryngeal neural circuit in experimentally induced laryngeal inflammation. Acta Otolaryngol . 2005;125:184–190. 11. Birkent H, Maronian N, Waugh P, Merati AL, Perkel D, Hillel AD. Dosage changes in patients with long-term botulinum toxin use for laryngeal dys tonia. Otolaryngol Head Neck Surg . 2009;140:43–47. 12. Vasconcelos S, Birkent H, Sardesai MG, Merati AL, Hillel AD. Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia. Laryngoscope . 2009;119:2004–2007. 13. Chinosornvatana N, Tan M, Woo P. Adductor spasmodic dysphonia— changes in dosing after prolonged injections. Laryngoscope . 2011; 121(suppl 4):S168. 14. Braden MN, Johns MM 3rd, Klein AM, Delgaudio JM, Gilman M, Hapner ER. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception. J Voice . 2010;24:242–249.
Made with FlippingBook - Online Brochure Maker